Trishula Therapeutics reports results from Phase I trial of pancreatic cancer drug
US-based biotechnology company Trishula Therapeutics has reported positive results from its Phase I clinical trial of TTX-030, an anti-CD39 antibody…
All articles by Archana Rani
Archana Rani
-
-
Massive Bio launches Patient Connect portal to personalise cancer trial access
US-based oncology software company Massive Bio has launched Patient Connect, a free portal that aims to personalise access to cancer…
-
Autobahn Therapeutics starts trial of ABX-002 for major depressive disorder in adults
US-based biotechnology company Autobahn Therapeutics has begun the AMPLIFY Phase II trial, which is assessing ABX-002 as an adjunctive treatment…
-
AstraZeneca’s Imfinzi and Imjudo found to extend survival in liver cancer trial
UK-based pharmaceutical company AstraZeneca has reported positive results from the Phase III HIMALAYA trial of Imfinzi (durvalumab) plus Imjudo (tremelimumab)…
-
Johnson & Johnson’s RYBREVANT trial shows improved response rate
Johnson & Johnson has reported a 49% overall response rate in a colorectal cancer study with RYBREVANT (amivantamab-vmjw), in combination…
-
Novartis’ breast cancer trial of Kisqali reveals 28.5% risk reduction
Novartis has reported a 28.5% reduced risk of breast cancer recurrence in an updated analysis from the Phase III NATALEE…
-
Daiichi Sankyo posts positive DS-9606 clinical trial results in solid tumours
Daiichi Sankyo has reported positive initial findings from the dose escalation phase of the first-in-human Phase I trial of its…
-
Vico reports positive data from trial of VO659 for Huntington’s disease
Clinical-stage genetic medicines company Vico Therapeutics has reported positive interim data from its ongoing Phase I/IIa clinical trial of VO659,…
-
ImmPACT Bio’s cell therapy secures FDA approval for multiple sclerosis trial
ImmPACT Bio has secured investigational new drug (IND) application approval from the US Food and Drug Administration (FDA) for CD19/CD20-targeting…
-
TNF Pharmaceuticals to initiate MYMD-1 Phase II clinical trials
TNF Pharmaceuticals is set to initiate fully funded mid-stage Phase II clinical trials of its lead programme, MYMD-1, targeting sarcopenia.…